Study to Characterize Absorption, Distribution, Metabolism and Excretion of 14C PF-06651600 and to Evaluate the Absolute Oral Bioavailability and Fraction Absorbed of PF-06651600.
Study to Characterize Absorption, Distribution, Metabolism and Excretion of 14C PF-06651600 and to Evaluate the Absolute Oral Bioavailability and Fraction Absorbed of PF-06651600.
This study will investigate the absorption, distribution, metabolism and excretion (ADME) of
 14C PF-06651600 and characterize plasma, fecal and urinary radioactivity and identify any
 metabolites, if possible, of 14C PF-06651600 in humans.
Inclusion Criteria:

 -  Male participants who are healthy as determined by medical evaluation including a
 detailed medical history, full physical examination, including blood pressure (BP) and
 pulse rate (PR) measurement, 12 lead ECG, and clinical laboratory tests.

 -  Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).

 Exclusion Criteria:

 -  Known immunodeficiency disorder, including positive serology for human
 immunodeficiency virus (HIV) at screening, or a first degree relative with a
 hereditary immunodeficiency.

 -  Infection with hepatitis B or hepatitis C viruses.

 -  Participants with selected acute or chronic infections or infection history.

 -  Participants have a known present or a history of malignancy other than a successfully
 treated or excised non metastatic basal cell or squamous cell cancer of the skin.

 -  History of alcohol abuse or binge drinking and/or any other illicit drug use or
 dependence within 6 months of Screening.

 -  Use of tobacco/nicotine containing products within 3 months prior to dosing or
 positive urine cotinine test.